MX369004B - Composiciones orgánicas para tratar las enfermedades relacionadas con hsf1. - Google Patents

Composiciones orgánicas para tratar las enfermedades relacionadas con hsf1.

Info

Publication number
MX369004B
MX369004B MX2017007968A MX2017007968A MX369004B MX 369004 B MX369004 B MX 369004B MX 2017007968 A MX2017007968 A MX 2017007968A MX 2017007968 A MX2017007968 A MX 2017007968A MX 369004 B MX369004 B MX 369004B
Authority
MX
Mexico
Prior art keywords
strand
diseases1
hsf
treat
organic compositions
Prior art date
Application number
MX2017007968A
Other languages
English (en)
Inventor
Hinkle Gregory
Milstein Stuart
Zhou Wenlai
Kuchimanchi Satyanarayana
Warmuth Markus
Zhu Ping
S Zimmermann Tracy
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MX369004B publication Critical patent/MX369004B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/322—2'-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/31—Combination therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/50—Methods for regulating/modulating their activity
    • C12N2320/51—Methods for regulating/modulating their activity modulating the chemical stability, e.g. nuclease-resistance
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/50—Methods for regulating/modulating their activity
    • C12N2320/53—Methods for regulating/modulating their activity reducing unwanted side-effects
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • AIDS & HIV (AREA)
  • Transplantation (AREA)
  • Hematology (AREA)

Abstract

La presente invención se refiere a una composición que comprende un agente de ARNi para HSF1 que comprende una primera cadena y una segunda cadena, en donde la secuencia de la primera cadena comprende la secuencia de SEQ ID NO: 681, en donde la primera y/o la segunda cadena se modifican, y en donde la primera cadena es de aproximadamente 30 o menos nucleótidos en longitud. La composición para usarse en la inhibición de la expresión de HSF1 en un sujeto afectado con cáncer.
MX2017007968A 2009-12-18 2010-12-16 Composiciones orgánicas para tratar las enfermedades relacionadas con hsf1. MX369004B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28813709P 2009-12-18 2009-12-18
PCT/EP2010/069917 WO2011073326A2 (en) 2009-12-18 2010-12-16 Organic compositions to treat hsf1-related diseases

Publications (1)

Publication Number Publication Date
MX369004B true MX369004B (es) 2019-10-24

Family

ID=43646461

Family Applications (3)

Application Number Title Priority Date Filing Date
MX2012007032A MX339050B (es) 2009-12-18 2010-12-16 Composiciones organicas para tratar las enfermedades relacionadas con hsf1.
MX2015013656A MX348526B (es) 2009-12-18 2010-12-16 Composiciones orgánicas para tratar las enfermedades relacionadas con hsf1.
MX2017007968A MX369004B (es) 2009-12-18 2010-12-16 Composiciones orgánicas para tratar las enfermedades relacionadas con hsf1.

Family Applications Before (2)

Application Number Title Priority Date Filing Date
MX2012007032A MX339050B (es) 2009-12-18 2010-12-16 Composiciones organicas para tratar las enfermedades relacionadas con hsf1.
MX2015013656A MX348526B (es) 2009-12-18 2010-12-16 Composiciones orgánicas para tratar las enfermedades relacionadas con hsf1.

Country Status (14)

Country Link
US (8) US8293718B2 (es)
EP (4) EP3406720A1 (es)
JP (2) JP5819848B2 (es)
KR (2) KR101605932B1 (es)
CN (2) CN105125572A (es)
AR (1) AR079494A1 (es)
AU (1) AU2010332881B2 (es)
BR (1) BR112012014760A2 (es)
CA (2) CA2784783C (es)
HK (1) HK1214949A1 (es)
MX (3) MX339050B (es)
TW (1) TWI576108B (es)
UY (1) UY33114A (es)
WO (1) WO2011073326A2 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003261231A1 (en) * 2002-07-26 2004-02-16 Chiron Corporation Modified small interfering rna molecules and methods of use
ES2441791T3 (es) * 2004-10-01 2014-02-06 Novartis Vaccines And Diagnostics, Inc. Moléculas de ARN de interferencia pequeñas modificadas y métodos de uso
US8765704B1 (en) 2008-02-28 2014-07-01 Novartis Ag Modified small interfering RNA molecules and methods of use
CA2784783C (en) 2009-12-18 2021-07-20 Novartis Ag Organic compositions to treat hsf1-related diseases
EP3521432A1 (en) 2011-09-02 2019-08-07 Arrowhead Pharmaceuticals, Inc. Organic compositions to treat hsf1-related diseases
CA2860676A1 (en) * 2012-01-09 2013-07-18 Novartis Ag Organic compositions to treat beta-catenin-related diseases
MX361680B (es) * 2012-12-13 2018-12-13 Aduro Biotech Inc Composiciones que comprenden dinucleótidos de purina cíclicos que tienen estereoquímicas definidas y métodos para su preparación y uso.
GB201317609D0 (en) 2013-10-04 2013-11-20 Cancer Rec Tech Ltd Inhibitor compounds
EP3119888B1 (en) 2014-03-19 2021-07-28 Ionis Pharmaceuticals, Inc. Compositions for modulating ataxin 2 expression
GB201505658D0 (en) 2015-04-01 2015-05-13 Cancer Rec Tech Ltd Inhibitor compounds
GB201617103D0 (en) 2016-10-07 2016-11-23 Cancer Research Technology Limited Compound
FR3082274B1 (fr) 2018-06-06 2021-11-19 Gaztransport Et Technigaz Cuve etanche et thermiquement isolante
CA3106986A1 (en) 2018-07-25 2020-01-30 Ionis Pharmaceuticals, Inc. Compounds and methods for reducing atxn2 expression
CN113862361B (zh) * 2021-10-25 2023-08-15 中山大学孙逸仙纪念医院 一种诊断和治疗膀胱癌的分子标志物hsf1及其用途

Family Cites Families (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6696561B1 (en) 1909-07-09 2004-02-24 Basf Aktiengesellschaft Corynebacterium glutamicum genes encoding proteins involved in membrane synthesis and membrane transport
US4475196A (en) 1981-03-06 1984-10-02 Zor Clair G Instrument for locating faults in aircraft passenger reading light and attendant call control system
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US5030453A (en) 1983-03-24 1991-07-09 The Liposome Company, Inc. Stable plurilamellar vesicles
US4486194A (en) 1983-06-08 1984-12-04 James Ferrara Therapeutic device for administering medicaments through the skin
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US5374548A (en) 1986-05-02 1994-12-20 Genentech, Inc. Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor
MX9203291A (es) 1985-06-26 1992-08-01 Liposome Co Inc Metodo para acoplamiento de liposomas.
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US5108921A (en) 1989-04-03 1992-04-28 Purdue Research Foundation Method for enhanced transmembrane transport of exogenous molecules
US5032401A (en) 1989-06-15 1991-07-16 Alpha Beta Technology Glucan drug delivery system and adjuvant
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
US6977244B2 (en) 1996-10-04 2005-12-20 Board Of Regents, The University Of Texas Systems Inhibition of Bcl-2 protein expression by liposomal antisense oligodeoxynucleotides
US7053052B2 (en) * 1997-01-21 2006-05-30 Voellmy Richard W Therapies involving mutated heat shock transcription factor
US5891467A (en) 1997-01-31 1999-04-06 Depotech Corporation Method for utilizing neutral lipids to modify in vivo release from multivesicular liposomes
AR013269A1 (es) 1997-08-04 2000-12-13 Scras Producto que contiene por lo menos un rna de doble filamento combinado con por lo menos un agente anti-viral, para la utilizacion terapeutica en eltratamiento de una enfermedad viral, en especial de la hepatitis viral
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
KR20010042069A (ko) 1998-03-20 2001-05-25 베니텍 오스트레일리아 리미티드 유전자 발현 조절방법
AUPP249298A0 (en) * 1998-03-20 1998-04-23 Ag-Gene Australia Limited Synthetic genes and genetic constructs comprising same I
EP2267138B1 (en) 1998-04-08 2016-06-08 Commonwealth Scientific and Industrial Research Organization Methods and means for obtaining modified phenotypes
US6342596B1 (en) * 1998-05-05 2002-01-29 Hsf Pharmaceuticals S.A. Molecular regulatory circuits to achieve sustained activation of genes of interest by a single stress
GB9827152D0 (en) 1998-07-03 1999-02-03 Devgen Nv Characterisation of gene function using double stranded rna inhibition
EP2314700A1 (en) 1999-01-28 2011-04-27 Medical College of Georgia Research Institute, Inc Composition and method for in vivo and in vitro attenuation of gene expression using double stranded RNA
DE19956568A1 (de) 1999-01-30 2000-08-17 Roland Kreutzer Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens
BR0009884A (pt) 1999-04-21 2002-01-08 American Home Prod Processos e composições para a inibição da função das sequências de polinucleotìdeos
CA2378653A1 (en) 1999-07-09 2001-01-18 American Home Products Corporation Methods and compositions for preventing the formation of aberrant rna during transcription of a plasmid sequence
WO2001029058A1 (en) 1999-10-15 2001-04-26 University Of Massachusetts Rna interference pathway genes as tools for targeted genetic interference
GB9927444D0 (en) 1999-11-19 2000-01-19 Cancer Res Campaign Tech Inhibiting gene expression
DE10100586C1 (de) 2001-01-09 2002-04-11 Ribopharma Ag Verfahren zur Hemmung der Expression eines Ziegens
DE10160151A1 (de) 2001-01-09 2003-06-26 Ribopharma Ag Verfahren zur Hemmung der Expression eines vorgegebenen Zielgens
AU1767301A (en) 1999-11-29 2001-06-04 Cold Spring Harbor Laboratory Regulation of polycomb group gene expression for increasing seed size in plants
RU2164944C1 (ru) 1999-12-09 2001-04-10 Институт молекулярной биологии им. В.А. Энгельгардта РАН Способ изменения генетических свойств организма
US20050229272A1 (en) 1999-12-30 2005-10-13 Monica Driscoll Compositions and methods for gene silencing
IT1316982B1 (it) 2000-01-17 2003-05-26 Univ Roma Isolamento e caratterizzazione di un gene per il silenziamento genicoda n.crassa e suoi usi.
EP1272630A2 (en) 2000-03-16 2003-01-08 Genetica, Inc. Methods and compositions for rna interference
CA2403162A1 (en) 2000-03-17 2001-09-27 Benitec Australia Ltd. Genetic silencing
EP1268535B1 (de) 2000-03-22 2013-05-22 Sanofi-Aventis Deutschland GmbH Parkin aus c. elegans, nematode, der eine aberrante oder fehlende expression eines parkingens aufweist, und verwendungen davon
GB0007268D0 (en) 2000-03-24 2000-05-17 Cyclacel Ltd Cell cycle progression proteins
PT1309726E (pt) 2000-03-30 2010-03-08 Whitehead Biomedical Inst Mediadores de interferência por rna específicos de sequência de rna
CA2410947A1 (en) 2000-05-30 2001-12-06 Johnson & Johnson Research Pty Limited Methods for mediating gene suppresion by using factors that enhance rnai
US6680068B2 (en) 2000-07-06 2004-01-20 The General Hospital Corporation Drug delivery formulations and targeting
US7368248B2 (en) 2000-11-09 2008-05-06 Cenix Bioscience Gmbh Eukaryotic cell division genes and their use in diagnosis and treatment of proliferative diseases
KR100909681B1 (ko) 2000-12-01 2009-07-29 막스-플랑크-게젤샤프트 츄어 푀르더룽 데어 비쎈샤프텐 에.파우. Ｒｎａ 간섭을 매개하는 작은 ｒｎａ 분자
WO2002100435A1 (en) 2001-06-11 2002-12-19 Centre Hospitalier Universitaire De Montreal Compositions and methods for enhancing nucleic acid transfer into cells
CA2451247A1 (en) * 2001-06-22 2003-01-03 The Regents Of The University Of California Eukaryotic genes involved in adult lifespan regulation
EP1424998B1 (en) 2001-08-16 2010-05-26 The Trustees of The University of Pennsylvania Synthesis and use of reagents for improved dna lipofection and/or slow release prodrug and drug therapies
WO2003064625A2 (en) 2002-02-01 2003-08-07 Sequitur, Inc. Oligonucleotide compositions with enhanced efficiency
DE60334618D1 (de) 2002-06-28 2010-12-02 Protiva Biotherapeutics Inc Verfahren und vorrichtung zur herstellung von liposomen
KR20050084607A (ko) 2002-09-28 2005-08-26 매사추세츠 인스티튜트 오브 테크놀로지 인플루엔자 치료제
US7250496B2 (en) 2002-11-14 2007-07-31 Rosetta Genomics Ltd. Bioinformatically detectable group of novel regulatory genes and uses thereof
US8090542B2 (en) 2002-11-14 2012-01-03 Dharmacon Inc. Functional and hyperfunctional siRNA
EP2530155B1 (en) 2002-11-25 2016-03-16 Masafumi Matsuo ENA nucleic acid drugs modifying splicing in mRNA precursor
CA2506714A1 (en) 2002-11-26 2004-06-10 University Of Massachusetts Delivery of sirnas
WO2004064731A2 (en) 2003-01-14 2004-08-05 University Of Washington Lipid-drug formulations and methods for targeted delivery of lipid-drug complexes to lymlplhoid tissues
AU2003225410A1 (en) 2003-03-21 2004-10-11 Academisch Ziekenhuis Leiden Modulation of exon recognition in pre-mrna by interfering with the secondary rna structure
CN101291653B (zh) 2003-07-16 2012-06-27 普洛体维生物治疗公司 脂质包封的干扰rna
NZ545360A (en) 2003-08-28 2009-06-26 Novartis Ag Interfering RNA duplex having blunt-ends and 3'-modifications
WO2005032486A2 (en) * 2003-10-02 2005-04-14 Duke University A NOVEL SIRNA-BASED APPROACH TO TARGET THE HIF-α FACTOR FOR GENE THERAPY
AU2005248147A1 (en) * 2004-05-11 2005-12-08 Alphagen Co., Ltd. Polynucleotides for causing RNA interference and method for inhibiting gene expression using the same
US7795419B2 (en) * 2004-05-26 2010-09-14 Rosetta Genomics Ltd. Viral and viral associated miRNAs and uses thereof
US7740861B2 (en) 2004-06-16 2010-06-22 University Of Massachusetts Drug delivery product and methods
SI2206781T1 (sl) 2004-06-28 2016-05-31 The University Of Western Australia Protismiselni oligonukleotidi za induciranje preskakovanja eksona in postopki njihove uporabe
CN101184839A (zh) 2005-04-08 2008-05-21 纳斯泰克制药公司 用于呼吸道病毒感染的RNAi治疗
US8354384B2 (en) 2005-06-23 2013-01-15 Yale University Anti-aging micrornas
WO2007041294A2 (en) 2005-09-29 2007-04-12 The Trustees Of Boston University Methods for sensitizing cancer cells to inhibitors
CN101346393B (zh) 2005-11-02 2015-07-22 普洛体维生物治疗公司 修饰的siRNA分子及其应用
US7919603B2 (en) * 2005-12-19 2011-04-05 New York University Heat shock RNA
US20090011004A1 (en) 2005-12-30 2009-01-08 Philadelphia Health & Education Corp., D/B/A/ Drexel University Of College Of Medicine Improved carriers for delivery of nucleic acid agents to cells and tissues
GB0608838D0 (en) 2006-05-04 2006-06-14 Novartis Ag Organic compounds
WO2008022035A2 (en) 2006-08-10 2008-02-21 The Scripps Research Institute Methods for identifying cellular modulators of disaggregation activity or aggregation activity in an animal
CN101200721B (zh) * 2006-09-18 2011-06-08 复旦大学附属中山医院 人心肌保护基因及其用途
US7972870B2 (en) * 2007-02-02 2011-07-05 Dana-Farber Cancer Institute, Inc. Methods and compositions relating to the regulation of MUC1 by HSF1 and STAT3
US7858592B2 (en) * 2007-02-26 2010-12-28 The Board Of Regents Of The University Of Texas System Interfering RNAs against the promoter region of P53
WO2008141074A1 (en) 2007-05-10 2008-11-20 Salk Institute For Biological Studies Identification of compounds that protect against amyloid diseases
US8314227B2 (en) 2007-05-22 2012-11-20 Marina Biotech, Inc. Hydroxymethyl substituted RNA oligonucleotides and RNA complexes
AR066984A1 (es) * 2007-06-15 2009-09-23 Novartis Ag Inhibicion de la expresion de la subunidad alfa del canal epitelial de sodio (enac) por medio de arni (arn de interferencia)
EP2185702A4 (en) * 2007-08-21 2011-05-04 Scott And White Memorial Hospital And Scott Sherwood And Brindley Foundation METHOD AND COMPOSITIONS POST-TRANSLUCTIVE SWITCH-OFF
EP2238251B1 (en) 2007-12-27 2015-02-11 Protiva Biotherapeutics Inc. Silencing of polo-like kinase expression using interfering rna
WO2009103067A2 (en) 2008-02-14 2009-08-20 The Children's Hospital Of Philadelphia Compositions and methods to treat asthma
EP2451823A4 (en) * 2009-07-06 2013-07-03 Alnylam Pharmaceuticals Inc COMPOSITIONS AND METHODS FOR ENHANCING THE PRODUCTION OF A BIOLOGICAL PRODUCT
CA2784783C (en) * 2009-12-18 2021-07-20 Novartis Ag Organic compositions to treat hsf1-related diseases

Also Published As

Publication number Publication date
US9096637B2 (en) 2015-08-04
TW201130495A (en) 2011-09-16
US20140039039A1 (en) 2014-02-06
JP5819848B2 (ja) 2015-11-24
EP3000885B1 (en) 2018-07-25
WO2011073326A2 (en) 2011-06-23
KR101605932B1 (ko) 2016-03-24
EP3406720A1 (en) 2018-11-28
US20110166058A1 (en) 2011-07-07
US20120129915A1 (en) 2012-05-24
KR20160033251A (ko) 2016-03-25
WO2011073326A3 (en) 2011-08-11
CA2784783A1 (en) 2011-06-23
US8481509B2 (en) 2013-07-09
HK1214949A1 (zh) 2016-08-12
CN102686729A (zh) 2012-09-19
BR112012014760A2 (pt) 2016-06-14
JP2013514321A (ja) 2013-04-25
US10287582B2 (en) 2019-05-14
CA3112716A1 (en) 2011-06-23
EP3000885A2 (en) 2016-03-30
US8293718B2 (en) 2012-10-23
AR079494A1 (es) 2012-02-01
CN105125572A (zh) 2015-12-09
CA3112716C (en) 2026-01-06
US20220380775A1 (en) 2022-12-01
AU2010332881A1 (en) 2012-06-07
AU2010332881B2 (en) 2015-01-22
MX348526B (es) 2017-06-16
US20120129914A1 (en) 2012-05-24
US11091761B2 (en) 2021-08-17
EP3000885A3 (en) 2016-07-13
US12091661B2 (en) 2024-09-17
JP5981625B2 (ja) 2016-08-31
US8623838B2 (en) 2014-01-07
EP2513309A2 (en) 2012-10-24
US9540643B2 (en) 2017-01-10
MX2012007032A (es) 2012-07-04
KR20120104381A (ko) 2012-09-20
US20150284721A1 (en) 2015-10-08
US20170073678A1 (en) 2017-03-16
CA2784783C (en) 2021-07-20
CN102686729B (zh) 2015-09-23
JP2016026185A (ja) 2016-02-12
US20190276827A1 (en) 2019-09-12
EP3766976A1 (en) 2021-01-20
TWI576108B (zh) 2017-04-01
UY33114A (es) 2011-07-29
KR101718297B1 (ko) 2017-03-20
MX339050B (es) 2016-05-09

Similar Documents

Publication Publication Date Title
MX369004B (es) Composiciones orgánicas para tratar las enfermedades relacionadas con hsf1.
PE20210921A1 (es) Agentes arni como inhibidores de la transcripcion de la serpina 1 y composiciones que los comprenden
MX2012009180A (es) Variantes y composiciones que comprenden variantes con alta estabilidad en presencia de un agente quelante.
PE20211393A1 (es) COMPOSICIONES DE ARNi CONTRA EL COMPONENTE C5 DEL COMPLEMENTO Y METODOS PARA SU USO
UY32456A (es) Composicion famaceutica, forma farmaceutica, procedimiento para su preparación, metodos de tratamiento
TN2009000521A1 (en) Rnai inhibition of alpha-enac expression
UY34701A (es) Formas sólidas de un profármaco de nucleótidos de tiofosforamidato
BRPI0924653B8 (pt) composto de ferro-oligossacarídeo, composição e uso de deste composto
WO2014022739A3 (en) Modified rnai agents
CL2008003653A1 (es) Uso de un inhibidor de sglt derivado de glucopiranosilo y un inhibidor de dppiv seleccionado para tratar la diabetes; y composicion farmaceutica.
SV2010003673A (es) Compuestos heterociclicos novedosos y usos de los mismos
BRPI1000320B8 (pt) Composições e métodos para tratar sinais de envelhecimento da pele
UY33598A (es) Imidazopiridazinas sustituidas
BR112012031163A2 (pt) métodos de terapia combinada para tratamento de doenças proliferativas
MX339255B (es) Una para usarse en el rejuvenecimiento de la piel que comprende, eosina y , un oxidante y un factor cicatrizante.
CL2011001128A1 (es) Molecula de acido ribonucleico de doble cadena capaz de inhibir la expresion del gen del factor vii; secuencia de acido nucleico que codifica una cadena sentido y/o una cadena antisentido que estan comprendidas en dicha molecula de acido ribonucleico; composicion farmaceutica y su uso para tratar enfermedades tromboembolicas.
UY31816A (es) Agente para el tratamiento y/o prevención de una enfemedad autoinmune y para la formación de células t reguladoras
UA111464C2 (uk) Композиція, що містить моногліцериди органічних кислот c1-c7 та гліцерин, та її застосування як протибактеріального та протипліснявого засобу
BRPI1007302A2 (pt) composto, inibidor da produção de colágeno, e, agente para tratar doenças associadas com a produção excessiva de colágeno
BR112012018170B8 (pt) agente antimicrobiano para redução, inibição ou tratamento do crescimento microbiano, infecções microbianas, doenças inflamatórias, doenças ou condições virais resultantes de ou associadas aos mesmos
UA115652C2 (uk) Сполука, що містить модифікований олігонуклеотид, комплементарна mir-21
BR112014026740A2 (pt) anticorpo, composição, métodos para tratar um mamífero e para fornecer um anticorpo com adcc realçada, e, uso de um anticorpo
ECSP13012420A (es) Derivados de tetrahidro-pirido-pirimidina
CL2011002648A1 (es) Composicion topica que comprende un compuesto derivado de 1,2,4-tiadiazol o tiourea, un agente modificador de la viscosidad, un conservante y agua; estuche para la composicion; metodo para preparar la composicion; y uso para tratar una enfermedad o trastorno dermatologico mediado por un receptor de melanocortina tal como acne.
MX2013003076A (es) Terapeuticos contra cancer de mama.